CERUS CORP

CERUS CORP (CERS) is a US-listed equity tracked across major market indices. Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

The company reports trailing twelve-month revenue of $51.33M and net loss of $1.64M. Key metrics include a return on equity of -2.4%, a debt-to-equity ratio of 2.29.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for CERS to support both active traders and long-term investors.